Aspirin and tension-type headache

Farinelli, Ivano; Martelletti, Paolo

doi:10.1007/s10194-006-0357-4

Cited by 20 publications

(13 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a small single-blinded, randomized trial, metamizole, a pyrazole derivative analgesic, successfully aborted pain in episodic TTH [8]. Acetylsalicylic acid is effective, but its mechanism of action in headache is not yet fully elucidated, and new mechanisms are being unveiled, such as the induction of endogenous epimer lipoxins [9].…”

Section: Simple Analgesicsmentioning

confidence: 98%

Future therapeutic perspectives for tension-type headache

Lenaerts

2007

Current Science Inc

View full text Add to dashboard Cite

show abstract

Section: Simple Analgesicsmentioning

confidence: 98%

Future therapeutic perspectives for tension-type headache

Lenaerts

2007

Current Science Inc

View full text Add to dashboard Cite

show abstract

“…ASA is most important and well-known treatments [Farinelli et al, 2007]. However, the time of administration still constitutes a debating point.…”

Section: Nsaids Role In the Acute Treatment Of Headachementioning

confidence: 99%

Role of NSAIDs in acute treatment of headache

Martelletti¹,

Farinelli²,

Coloprisco³

et al. 2007

Drug Development Research

View full text Add to dashboard Cite

Headache is one of the most common neurological disorders worldwide. Tension-type headache (TTH) represents the most frequent headache form, involving 82% of sufferers. Of this population, 14% are affected by migraine and 4% by a chronic form of headache (chronic daily headache [CDH]). Nonsteroidal anti-inflammatory drugs (NSAIDs) represent the most used acute therapy for TTH and migraine because of issues with coxibs safety. NSAIDs play a minor role is the treatment in trigeminal-autonomic cephalgias (TACs); if excluding indomethacin in the acute management of paroxysmal hemicrania (PH). Despite limitations in their utilization, NSAIDs still constitute drugs of primary importance, being effective and being well tolerated in the treatment of acute episodes. © 2007 Wiley-Liss, Inc

show abstract

“…Their mechanism of action is expressed by inhibition of COX activity and the following decrease in prostaglandin (PG) synthesis [25].…”

Section: Ep 4 Receptor Antagonistsmentioning

confidence: 99%

Future drugs for migraine

et al. 2009

View full text Add to dashboard Cite

Migraine is a complex, neurovascular disorder in which genetic and environmental factors interact. At present, frontline therapies in the acute treatment of migraine include the use of non-steroidal anti-inflammatory drugs and triptans. Evidence indicates that calcitonin gene-related peptide (CGRP) plays a fundamental role in the mechanism of migraine. CGRP is a strong vasodilatatory neuropeptide that is released from activated trigeminal sensory nerves. The development of CGRP antagonists has also been driven by the fact that triptans are vasoconstrictive and cannot be safely used in patients with cardiovascular risk factors. Olcegepant (BIBN4096) is the first CGRP antagonist for the treatment of migraine that has been tested in clinical trials, but because of its poor oral bioavailability, only the intravenous formulation has been tested. The first oral non-peptide CGRP antagonist, telcagepant, has been shown recently to be highly effective in the treatment of migraine attacks. This development can be considered as the most important pharmacological breakthrough for migraine treatment since the introduction of sumatriptan in the early 1990s. These results are also of importance, since they support an interesting pathophysiological hypothesis of migraine. The pipeline of future compounds for the treatment of acute migraine headaches include TPRV1 antagonists, prostaglandin E receptor 4 (EP(4)) receptor antagonists, serotonin 5HT1(F) receptor agonists and nitric oxide synthase inhibitors. The immediate future of a preventative treatment for migraine headaches is well represented by botulinum toxin type-A, glutamate NMDA receptor antagonists, gap-junction blocker tonabersat and an angiotensin type 1 blocker candesartan.

show abstract

Aspirin and tension-type headache

Cited by 20 publications

References 63 publications

Future therapeutic perspectives for tension-type headache

Future therapeutic perspectives for tension-type headache

Role of NSAIDs in acute treatment of headache

Future drugs for migraine

Contact Info

Product

Resources

About